Navigation Links
Peripheral Artery Disease (PAD) Patent Granted to Dimera

PORTLAND, Ore., Aug. 11 /PRNewswire/ -- The U.S. Patent and Trade Office (USPTO) plans to announce patent award approval on August 11 to Dimera Incorporated for treatment of symptoms of Peripheral Arterial Disease (PAD), which is alternatively known as Peripheral Vascular Disease (PVD).

"Method and Kit for reducing the symptoms of peripheral vascular disease," (Number 7572780) covers the period August 11, 2009 through July 28, 2024. Dimera President, Prof. R. Kent Hermsmeyer, said, "We are pleased to announce perhaps the most important of the Dimera patents to date. Dimera plans to further optimize our success in demonstrating the virtues of our advanced transdermal strategy that we have extensively documented in primates to greatly extend normal function in the peripheral circulation."

Hermsmeyer explains that, "The loss of normal function of blood vessels explains deterioration of the peripheral circulation, and that decline in function with age now appears to be preventable. If women and men at the peak of cardiovascular health used our discovery to counter the avoidable fall in essential molecular function - which we have identified and mapped - then the expectation of reduced mobility and even disability with advancing age might be dispelled. Rather than addressing only the symptoms of peripheral vascular disease, Dimera has taken the demanding - but arguably more powerful - approach that demands discovery and understanding of the underlying molecular mechanism at the gene level."

The significance of this patent is one of the premiere successful translations of science - cell and molecular biology - to clinically effective medicine.

About Dimera

Founded by world-renown researchers in 1997 as a pure R&D biotech, Dimera ( has evolved into a drug development firm specializing in cardiovascular and smooth muscle diseases. Dimera has leveraged its expertise in physiology and biophysics into discovery of clinical applications for the prevention and treatment of cardiovascular disease. A systems approach integrating extensive preclinical coronary catheterization and molecular research have produced incisive definition of the molecular mechanism of action for steroid-mediated gene expression control.

Dimera's new drug platform is based on the discovery that low steroid levels directly control smooth muscle gene expression and thus reactivity. Smooth muscle in the wall of blood vessels, airways, and the bladder constitutes the essential (functional final common path) control element. In many cardiovascular diseases, vascular and visceral smooth muscle cell dysfunctions are a dominant direct cause of excessive constriction and obstructed flow.

SOURCE Dimera Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
2. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
3. ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
4. Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets
5. Peripheral Vascular Device Market Insights Webinar
6. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
7. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
10. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
11. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... Durham, NC (PRWEB) , ... June 23, 2016 , ... ... Odense University Hospital in Denmark detail how a patient who developed lymphedema after being ... (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
Breaking Biology News(10 mins):